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Abstract
Randomised controlled trials are the acknowledged ‘gold standard’ method of evaluating the effectiveness of
treatments, but little is known about how and why patients decide to participate in trials nor how much they understand
about trial design. In this study, in-depth, semi-structured interviews were carried out with 33 middle aged and older
men with lower urinary tract symptoms related to benign prostatic disease, 22 of whom had consented to participate
and 11 refused to take part in a randomised trial. The trial was evaluating the effectiveness of a new technology (laser
therapy) compared with standard surgery (transurethral resection of the prostate ) and conservative management
(monitoring without active intervention) (the CLasP study). Purposive sampling was used to include participants from
different centres, each treatment arm, and at different stages in participation, as well as those indicated to have refused
participation. Interviews explored their recall and understanding of trial information, and their reasoning about how
they were allocated to a treatment. Data were analysed thematically according to the methods of constant comparison,
and by examining each participant’s narrative of their experiences.
Most participants recalled major aspects of trial design, including the involvement of chance, but the case studies
showed that most also held other co-existing (and sometimes contradictory) views about their treatment allocation. The
key to understanding their experiences was their engagement in a struggle to understand the trial in the context of their
own beliefs, their recall of the study information and their actual experiences of the trial. The outcome of the struggle
was the placing of trust in clinicians or the development of distrust. Non-participants made sense of their experiences in
similar ways, but gave different reasons for non-participation than indicated by those not recruited.
This study shows that most eligible patients, whatever their level of knowledge, will struggle to make sense of their
participation in randomised trials. The provision of clearer written information or time to discuss the trial with
particular individuals might be beneficial, although greater public understanding of trials is also needed. r 2001
Published by Elsevier Science Ltd.
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Background
The demand for evidence about the effectiveness of
treatments has led to the increasing dominance in
funded health services research of the randomised
controlled trial (RCT). Historically, the literature
examining RCTs has tended to focus on the methodo-
logical issues that should be taken into account during
design and implementation, such as blinding and
placebos, ethical issues and informed consent (Pocock,
1983). Rather less research effort has concentrated on
investigating the patient’s perspective of participation,
and studies that have been conducted have tended to
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use hypothetical scenarios to determine willingness to
participate among the public, potential trial popula-
tions, specific treatment groups, or racial and ethnic
groups often underrepresented in trials (Cassileth, Lusk,
Miller and Hurwitz, 1982; Llewellyn-Thomas, McGreal,
Thiel, Fine and Erlichman,1991; Slevin et al., 1995).
Overall, such studies have found favourable attitudes
towards hypothetical trial participation, but a funda-
mental problem with such studies is their reliance on
attitudes to hypothetical (not real) trial participation.
Much of this literature has employed survey research
methods and structured questionnaires with the aim
of improving recruitment to future trials (Ross et al.,
1999). Studies have identified altruism, trust in recruiting
clinicians, and an expectation of personal benefit as the
main motives for participation in trials (Daugherty et al.,
1995; Charles, Redko, Whelan, Gafni, & Reyno, 1998).
Numbers and reasons for refusals to participate appear
to vary according to the type of trial and the severity
of treatment (Riordan & Thomson, 1996). In a
qualitative study of an HIV trial, for example, issues
of confidentiality were particularly important because of
fears of being identified as having a disease that assumed
specific social or sexual identity (Ryan, 1995).
Such barriers would not necessarily extend to other
trials. In most studies, there was often an expectation
that design issues would be an important reason for
refusal to participate, but the evidence is somewhat
mixed. In the majority of studies, only small numbers
cited a dislike of being randomised or the use of a
placebo or experimentation as the reason for refusal
(Schwartz & Fox, 1995; Mohanna & Tunna, 1999)
although in studies of women with breast cancer,
objection to randomisation was given as the main
reason for refusal among half of those questioned
(Alderson, 1996). Other important factors for refusing
to participate included inconvenience, difficulties with
transport, too many clinic visits and time taken, as
well as a distrust of medicine or the hospital and worries
about side effects (Schwartz & Fox, 1995; Bevan,
Chee, McGhee, & McInnes, 1993). Reasons for non-
participation have been highlighted as an important area
for further research in a recent systematic review (Ross
et al., 1999).
There is a small but increasing number of studies
focusing on the perspectives of actual participants in
trials, asking them to describe their experiences of
participation and reflections on their motives for taking
part, using in-depth, semi-structured interviews (Snow-
don, Garcia, & Elbourne, 1997; Appelbaum, Roth, Lidz,
Benson, & Winslade, 1987). In a UK study, Snowdon
et al. (1997) carried out interviews with 37 parents (21
couples) who agreed to the participation in a trial of
their new-born child with acute respiratory failure. In
the other, Appelbaum et al. (1987) observed the
informed consent process and conducted interviews with
patients immediately afterwards in four US trials of
treatment for psychiatric illness.
These studies found that many trial participants did
not believe that chance was involved in their treatment
allocation. A third of the psychiatric patients (Appel-
baum et al., 1987) and many parents (Snowdon et al.,
1997) believed they had been allocated on the basis of
their individual therapeutic needs. Both papers con-
cluded that trial participants may systematically mis-
interpret the underlying scientific methodology and
hence participate in the trial because of their belief in
personalised care (Snowdon et al., 1997; Appelbaum
et al., 1987). Although participants’ descriptions of the
trial seemed correct, further scrutiny often revealed
‘distortions’ of the intentions of the randomised
controlled trial. Appelbaum et al. (1987) referred to this
denial of random allocation as the ‘therapeutic mis-
conception’ (p. 20) and suggested that patients filled
such ‘vacuums of knowledge’ by constructing ‘elaborate
but entirely fictional’ (p. 21) accounts of their treatment
assignment. Snowdon et al. (1997) additionally con-
cluded that most parents were ‘confused’ about rando-
misation and the methodology of the trial. A recent
systematic review of informed consent similarly sug-
gested that ‘‘patients do not always grasp what
information is disclosed to them’’, resulting in ‘‘defects
in reasoning’’ (Edwards et al., 1998, p. 44).
The aim of our study was to explore whether these
issues were congruent with the experiences of middle
aged and older men taking part or having decided not to
participate in a pragmatic randomised controlled trial of
treatments for a common and non-life-threatening
conditionFlower urinary tract symptoms related to
benign prostatic disease. In particular, we sought to
examine their recall of the study information and
attitudes towards participation, and then their reasons
for agreeing to participate in the trial or not, and their
views about their ultimate treatment allocation.
Methods
The main trial
Both authors worked in a department where a range
of randomised controlled trials were being undertaken.
The trial chosen for this study was one that was being
led by one of the authors (JD) to facilitate access to
patients and study information. The trial, known as
CLasP (the acronym relating to the treatments in-
volved), aimed to compare the effectiveness of laser
therapy (a new technology), standard surgery (transur-
ethral resection of the prostateFTURP), and conserva-
tive management (monitoring without active
intervention) in middle aged and older men with
common urinary symptoms. There were three linked
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trials: all three treatments were compared in men with
uncomplicated lower urinary tract symptoms, and laser
therapy and TURP alone were compared for men with
acute or chronic retention of urine in whom immediate
treatment was required (Donovan et al., 2000; Gujral
et al., 2000; Chacko et al., in press).
Standard trial procedures were followed. There was a
process of written informed consent, completion of
questionnaires and clinical tests to establish eligibility,
with treatments then allocated by clinical researchers
opening consecutive opaque envelopes based on rando-
misation schedules generated by a researcher not
involved in the study. At an early stage, patients were
given an information sheet, which included details about
each of the treatments and described the study in the
following terms:
(a) that it was an experimental study because one of the
treatments (laser therapy) was new;
(b) that the aim of the RCT design was to allow the
treatments to be compared;
(c) that the treatment allocation would be by chance;
(d) that there was clinical uncertainty about which
treatment was best;
(e) that the allocation would be concealed to both
patient and clinician and that a clinician would
open a sealed envelope to reveal the treatment
allocation.
The qualitative study
Qualitative research methods were used to explore
both participants’ and non-participants’ views, attitudes
and experiences (Pope & Mays, 1995).. Purposive
sampling was used to ensure that individuals with a
range of characteristics were included. Thus, within this
study participants (n ¼ 22) in the CLasP trial and men
who chose not to participate for a range of reasons
(n ¼ 11) were interviewed.
The sample included participants from each of the
two major clinical centres, in the different arms of the
trial, and at different time points after randomisation.
Non-participants were identified from the trial records
as having refused to participate for three major reasons:
they had a treatment preference, did not want to be
randomised or take part in research, or did not want to
undergo tests that were part of the recruitment process.
One patient where no motive had been recorded was
also selected.
Data were collected by semi-structured in-depth
interviews (carried out by KF) using a checklist of
topics to guide the discussion (Burgess, 1982; Mays &
Pope, 1996). Interviews were conducted in the men’s
homes, audio-tape recorded and lasted from half and
hour to one and a half hours. Each interview was
transcribed as fully as possible. Data collection (inter-
views) and data analysis continued concurrently, ac-
cording to the constant comparison methods of
grounded theory in which data are examined for
similarities and differences within themes, retaining the
context of the discussion and characteristics of the
individuals to aid understanding and allow interpreta-
tion and development of explanations of findings
(Glaser & Strauss, 1967).
The data were analysed in several ways. The men’s
recall of each of the five aspects of the trial (see a–e
above) was assessed by KF and JD jointly and matrices
were drawn up to show which men understood which
aspects of trial design. Detailed descriptive accounts of
emergent themes were produced by KF and checked by
JD. The data were examined for patterns and themes, by
contrasting and comparing accounts, noting surprising
or puzzling findings for more detailed scrutiny. The data
revealed a number of complex and somewhat confusing
themes and so it was decided that detailed case studies
would be produced for each respondent describing and
charting his attitudes and experiences. These case studies
were also checked by JD. Typologies were also used to
examine why certain strategies were adopted by some
subjects by tracing conditional paths to track the process
of an event (Strauss & Corbin, 1990). The case studies
illuminated the various strategies employed by each
participant to explain their treatment allocation. In the
light of these case studies, all the original transcripts
were re-examined to check and verify the concepts and
to take account of the context of the data.
The data are presented below within the major themes
that emerged from the interviews with quotations to
illustrate the findings and allow the reader to judge
interpretations. All names and places have been changed
to preserve anonymity.
Results
Thirty-three men potentially eligible for the CLasP
trials were finally interviewedF22 participants and 11
non-participants. Men with a range of ages, from each
of the clinical centres and in each of the arms of the trial
were interviewed. Seven participants were interviewed
within three months of being randomised, five within
five months, and eight after at least six months, by which
time they had completed their treatment and had been
followed up. The majority of the non-participants
attended clinic B and had not yet received treatment
for their condition. The men were aged 54–81 years old
and were predominantly retired.
A number of major themes emerged from the data,
some of which appeared to be contradictory. Detailed
scrutiny of these themes in the light of the individual
case studies showed that the material represented a
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struggle that the men engaged in to make sense of their
experiences. First, the men’s recall of the trial methods is
presented, including both participants and non-partici-
pants together. Then the reasoning employed by the
participants to explain their participation in the trial is
presented. Finally, the different pathways to non-
participation are described.
Recall of trial design
Participants had greater overall recall than non-
participants about the design issues in the trial. About
half or more of the participants recalled that the study
involved experimentation, the comparison of treatments
and allocation by concealment, usually by envelopes.
While non-participants had lower levels of recall of most
design aspects, almost all recalled the experimental
nature of the trial and emphasised this aspect consis-
tently more often than the participants. Only one
participant (Mr Mott) and two non-participants (Mr
Flynn and Mr Allgood), could remember none of the
major design aspects, and similarly, only two men, one
participant (Mr Murray) and one non-participant (Mr
Becker), could recall all five.
Almost all (15) of the participants acknowledged the
involvement of chance in their allocation:
There were those three things [y] and he said oh yes
you’ve got a swollen prostate, you’ll probably have to
have an operation but it’s a chance you might take,
which one of them you take, it comes out the hat,
sort of thing you know. It’s out of the hat you cannot
pick. [Mr Symonds: participant allocated to CM]
In contrast, only four non-participants could recall
that chance was involved:
Yes he did list for me, outline the various different
methods, that’s right, and explain to me that your
particular case would be treated by lottery if you like,
by picking up an envelope and that was to be it. [Mr
Ladbroke: non-participant, a dislike of randomisa-
tion]
Twelve participants and four non-participants were
aware that the trial involved the comparison of
treatments:
But the scheme itself was I think they wanted to
compare, they wanted to do all three and then make
a comparison of what the end results were. So after
six months or whatever they are going to do it for,
they assess it and I suppose the replies that I’m giving
will help to decide what was going to go on in the
future. [Mr Murray: participant allocated to TURP]
Overall, 13 participants and only three non-partici-
pants could recall that allocation to a treatment would
be concealed:
And of course at the same time explained that neither
she or the consultant himself knew which I would get
until they chose this famous envelope, one of two
envelopes. [Mr Taylor: participant allocated to and
preference for TURP]
You will be allowed to pick an envelope and one will
say laser and one will say surgery. Whichever you
pick you’ll get. [Mr Becker: non-participant refused
trial tests]
Fourteen participants and only two non-participants
recalled hearing that consecutive opaque envelopes were
involved in the trial treatment allocation:
They pick theFthey have three envelopes or some-
thingFand they chose the envelope where they
weren’t going to do nothing and the specialist said
that was sort of good really. [Mr Cullum: participant
allocated to CM, no preference]
Eleven participants and almost all (9) of the non-
participants knew that the trial was an experimental
study of some sort, involving ‘guinea pigs’:
It was ideal, no problem, no problem. They have got
to have these experiments and this sort of thing and I
was quite prepared you know, they’ve got to learn
somewhere, somewhere along the line you know. [Mr
Daw: participant allocated to CM]
Well all they were doing at that moment in time, they
were doing so many with surgery and so many with
laser and they were using people like guinea pigs too.
[Mr Becker: non-participant refused trial tests]
Knowledge of clinical uncertainty was at a much
lower level with only six participants and four non-
participants indicating an understanding of this:
Well y no because as they say, when they spoke
about the two operations they explained to me then
that the results should be the same all things being
equal. Fair enough if that’s the way. [Mr Taylor:
participant allocated to TURP]
I think I would have thought well either have it cut
out or have it lasered out. It wouldn’t make no odds
as long as it does the job. Yeah, I mean I wouldn’t
have, I don’t think I would have minded either way
there. [Mr Young: non-participant travel,]
Levels of recall were examined in relation to various
patient characteristics, but, other than participation, no
clear patterns were apparent. For example, the eight
men who could recall four or more of the trial concepts
had been allocated to a range of treatments, represented
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both trial centres and had been interviewed between
three and eight months after randomisation or ‘refusal’.
Age and time after randomisation appeared to have little
influence on these men’s recall and understanding of
trial information. The influence of social class was also
examined. It is often stated that obtaining informed
consent to participate in a trial from poorly educated
patients is a ‘sham’ (Editorial, BMJ, 1995). However,
the eight ‘middle class’ men had varying levels of recall
and understanding of these five elements, ranging from
the highest (Mr Murray) to one of the lowest (Mr
Bullock).
Participants: the struggle to make sense of participation
Whilst the majority of participants had a good or
partial recall of the major aspects of trial design and
methods, many indicated in their interviews that they
had difficulties understanding the terminology and
coming to terms with the concepts inherent in the trial
design. The case studies of each man showed that all
were involved in what was, essentially, a struggle to
make sense of their participation. Table 1 outlines the
major explanations given by the men to describe their
understanding of how they wanted to be, or thought
they had been, allocated to a treatment. Their views
appeared to arise from two main sources: their expecta-
tions about the way they thought they ought to be
treated and their actual experiences of participating in
the trial. These factors were closely linked to the
presence of fatalism and trust or distrust of the study
and clinical staff, which in turn fed back into a
confirmation or undermining of what they understood
about trial design. There appeared to be no consistent
relationship between the level of recall of trial elements
and the presence of alternative and fluctuating view-
sFin most men, these were coexistent.
Individualised treatment
Just over half of the participants (12) indicated that
they had expected to receive treatment based on their
diagnosis and an assessment of their specific needs by a
clinician or practical issues, in the way that they
perceived normal clinical practice to occur. Their
experience of completing several questionnaires and
various clinical tests and examinations within the trial
helped to reinforce this belief:
Well I think it was based on the tests that they gave
me and it was one of the types. I think this was for
a scan on my bladder to see if it was empty and
everything and [the recruiting clinician] came back
and she says to us reading the notes and every-
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Table 1
Alternative ‘non-randomised’ explanations of treatment allocation
The five elements of the RCT Participant Rationing Individualised allocation Fate/destiny Trust Distrust
5 Mr Murray | |
5 Mr Taylor |
5 Mr Pierce | | |
5 Mr Houghton | | |
5 Mr Hall | | | |
5 Mr Daw |
4 Mr Cooper |
4 Mr Booth | |
4 Mr Flint | |
4 Mr Cullum | |
3 Mr Bowler | | |
3 Mr Formby | | |
3 Mr Symonds | | |
2 Mr Jamison | | |
2 Mr Grange | | |
2 Mr Stone | | |
2 Mr Brown | | |
2 Mr Mills | |
2 Mr Watson | |
1 Mr Webster |
1 Mr Bullock | | | |
0 Mr Mott
5 12 13 10 11
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thing and what had happened up to then as regards
my case, in their opinion as well the middle operation
was the best option they thought. [Mr Watson:
participant allocated to TURP]
But I thought they would probably they’re only
picking ones that are retired for doing that [con-
servative management]. I can’t see them having fellas
who are going to work because they wouldn’t be able
to do it. [Mr Symonds: participant allocated to CM
and preferred active treatment]
Rationing
Five participants thought that the study involved the
rationing of treatments. Mr Bullock implied that the
rationale for allocating him to a treatment was because a
patient was needed to fill the quota for the laser
treatment at the time he attended the clinic:
Well I think I was slightly cynical about it, I didn’t
really believe it. I thought that they, you know
that...I really thought that they were just going to
divide people up. I thought it was a bit of a con. [Mr
Bullock: participant allocated to and preferred laser]
These participants thought that randomisation was
being used by the clinicians/the NHS as a way of
rationing scarce resources. This was believed to be
related to waiting list size, the limited availability of one
of the treatments or cost (laser required a shorter
hospital stay and conservative management effectively
no additional costs at all). Such beliefs were often based
on these patients’ experience of receiving treatment.
Within this trial, laser patients were grouped together to
use the laser machine in one surgical session. Hence
patients receiving either laser or TURP tended only to
see other patients receiving the same treatment as
themselves:
Whether or not there is a chance of you getting a
treatment in there I don’t know. But I asked others
afterwards and they all said the same, they all said
the same as me. I never got any chance of getting
laser. Cos I says to her, can I have the laser. [Mr
Symonds: participant allocated to CM and preferred
active treatment]
Fate and destiny
Almost two-thirds of the participants described
in detail their belief that fate or destiny played a
role in their (randomised) treatment allocat-
ion. These beliefs were particularly strong when
patients obtained the treatment they had apparently
preferred:
I was convinced from the start that I was going to
have a laser operation. I felt that that was what was
going to be the result. I don’t think the envelopes
would’ve mattered. [Mr Grange: participant allo-
cated to and preferred laser]
I preferred the one that I got, so I must have been
lucky. I wasn’t too keen on this laser idea of having
the tube through the stomach into the bladder. [Mr
Cooper: participant allocated to and preferred
TURP]
Trust and the development of distrust
Trust in the clinician involved in the trial or doctors in
general was apparent in many of the accounts.
Typically, this trust was expressed in terms of the doctor
being an expert:
It didn’t worry me too much. I thought they know
what they’re doing like, you know, so I sort of I’m in
their hands like sort of thing, that’s the attitude I
took, they know more about it than what I know
about it like you know. [Mr Cullum: participant
allocated to CM]
The laser one he said was more of an experimental
one, how would I feel about it. I said whatever you
think is best, you know. I mean I’m a layman, I don’t
know what goes on so I’ve got to leave it to them.
[Mr Stone: participant allocated to laser]
The trust in doctors extended to trust in the trial itself:
You know I’m quite prepared to accept the fact that
these guys have to learn their profession the same as
everyone else. [Mr Houghton: participant allocated
to and preferred laser]
However, for 11 of these participants, their experi-
ences led to the development of distrust. For some,
difficulties in making sense of randomisation led to
cynicism:
You know, you’ll know for a fact that they’re giving
you the choice of picking one but you’re saying to
yourself, no matter which one you pick, you’re not
getting onto the other one. [y] Yes, I think that, I
don’t know mind. But I think it’s obviously they
decide on what, what they’ve found out on examining
you I think they decide which is going to be best for
you. That’s only to keep you happy I think. [Mr
Symonds: participant allocated to CM]
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Well I think I was slightly cynical about it, I didn’t
really believe it. I thought that they, you know
thatyI really thought that they were just going to
divide people up. I thought it was a bit of a con. [Mr
Bullock: participant allocated to laser]
For Mr Mills, distrust developed because he was
unable to accept that randomisation could be a sensible
alternative to receiving treatment according to clinical
need. He wanted the doctors to tell him what treatment
would be most suitable for him, and perceived the trial
to be ‘a trick’:
They still let you do the three card trick and they just
carry it on because from the very first start it’s
written in the pamphlets they give you. That’s one of
the things they’ll do. You’ve got your three
choices[y] but I think it would be even better if
they were to tell you that they prefer, that you’re
going to get. Because after all with, it’s going to be
the first time for everybody, you don’t have this thing
done twice. So therefore, after all if they tell you you
still don’t know what it’s going to be so it makes no
differencey [Mr Mills: participant allocated to CM]
For the majority of those who expressed distrust, this
could be tempered by a successful outcome. For
example, in contrast to Mr Symonds above, where the
failure to obtain his preference led to distrust, the fact
that Mr Grange received his preferred treatment seems
to have outweighed any suspicion of how this actually
occurred:
I was convinced from the start that I was going to
have a laser operation. I felt that that was what was
going to be the result. I don’t think the envelopes
would’ve mattered. [Mr Grange: participant allo-
cated to and preferred laser]
Treatment preferences
The type of treatment received by the men appeared
to have some influence on their views. It is important to
bear in mind that these are preferences described after
the process of randomisation and it is not possible to
know whether these preferences were present earlier.
The preferences expressed by the men suggested that
half were randomised to the treatment they suggested
they had preferred (see above). Eight participants,
however, appeared to have been randomised to a
treatment that was not their original or rationalised
preference. Interestingly, the majority of this group
appeared to be satisfied with their allocation, perhaps
because they received one of the active treatments (laser
or TURP). Five men (Mr Formby, Mr Mills, Mr
Symonds, Mr Daw and Mr Jamison) preferred TURP
or laser, but had been allocated to conservative manage-
ment. They had been assured that they would receive
active treatment (TURP) once they had completed the
trial.
However, a few participants found their allocation to
conservative management difficult to accept. Despite
being able to recall the involvement of chance in their
allocation, these participants also wanted and expected
‘treatment’. Conservative management was interpreted
as exclusion from treatment and this was upsetting for
these patients:
You know at the moment, as I said like, the problem
with this water trouble is you know four or five times
every night and it’s a bit annoying you know. I can
go to the toilet, come downstairs and within a matter
of minutes I’ve got to rush back upstairs. Well I think
something ought to be done about it. [y] I naturally
thought that they were going to do something about
it but as I said I had no tablets or nothing for it, so
that’s all I can tell you. [Mr Jamison: participant
allocated to CM but preferred active treatment]
Non-participants: pathways to refusal
Although reasons for refusal were written by recruit-
ing clinicians in the patients’ notes, it quickly became
apparent in the interviews that patients often gave very
different explanations of their ‘refusal’. In the interviews,
five were able to cite clear and particular reasons for
non-participation. However, there was less clarity
among the remaining ‘refusers’, with three indicating
that they had treatment preferences but thought they
were participants in the trial, and three who could not
recall the trial or being asked to take part. Each of these
groups is considered below.
Active refusers
The non-participants who appeared to have made an
active decision not to take part in the trial (Mr Young,
Mr Ladbroke, Mr Frost, Mr Gibbon and Mr Williams)
had a good recall of the trial in terms of experimenta-
tion, but low levels of recall of the other design aspects.
All expressed a clear treatment preference, the majority
wanting TURP because they believed this to be the
standard and most effective treatment:
Well I think me being me, if the TURPs is the
standard one then I’m quite happy thank you
because that’s been proven with everyone else.
Having said that I appreciate someones got to do,
you’ve got to have someone for research. But me
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worrying, no thank you, [Mr Gibbon: non-partici-
pant treatment preference]
The decision not to participate was made by Mr
Young because he perceived no direction from the
clinician about the trial:
When he said ‘well its entirely up to you’ he didn’t
seem to want to make any decisions or choices for me
and so I said well I thought the easiest option, the
thing is to go for the operation because I’ve been told
about it before.[Mr Young: non-participant travel]
Mr Gibbon, however, felt he had been directed away
from the trial because of his uncertainty:
I wasn’t expecting this to be honest. I thought it was
‘here take these pills you’ll be OK’,yI think my face
must have changed and then [the recruiting clinician]
said I don’t think this is for you, I don’t think it’s in
your best interest for you to, and I agreed. [Mr
Gibbon: non-participant treatment preference]
Mr Ladbroke believed the clinician tried to force him
into the trial:
I said give us the pills, I thought I’ll have the pills
thank you very much! (Laughs)[y] He was defi-
nitely, yes he gave me the impression, perhaps
wrongly, that he was er having trouble getting
anyone submitting themselves to the trial (laughs).
[Mr Ladbroke: non-participant a dislike of randomi-
sation]
It is interesting that the perception of different
direction from the clinician could lead to eventual
non-participation. It also appears that some of these
non-participants were eased away from the trial by
clinicians.
‘Inactive’ refusers
Three patients with high levels of recall of trial design
issues were confused that they had been labelled
‘refusers’. All had indicated that they would have been
willing to accept trial participation, but there were also
hints in their accounts that they had expressed treatment
preferences which might have led to the clinicians
deciding that they had refused:
He went on to say to me would I be interested in a
laser job? I said that would suit me fine. So he went,
he left the room and went out, spoke to someone,
came back in and said ‘well it appears that it’s not
bad enough for a laser job’ So I said well OK. So
then he surprised me again and said ‘now I can still
put you down for an operation’ So I said ‘well, OK’
In the notes it stated that you would prefer the
operation...
No that’s not correct at all, I accepted what was
offered to me. I was prepared to accept anything that
was offered to me. [Mr Maynard: non-participant
treatment preference]
He did say that all three methods really are quite OK
and they are quite happy with all three methods but
er you know what suits some may not necessarily suit
someone else. So the impression I got was that it
would be as a result of talking to me about it before it
was decided. [Mr Maynard: non-participant treat-
ment preference]
Well I self-allocated to the watch and wait. Of course
they did mention the main side effects, well of course
the main side effects is that you can become sterile
[y]But that’s the position with me, watching and
waiting, sort of putting it off I suppose, I don’t know.
[Mr McCarthy: non-participant treatment prefer-
ence]
No recall of being asked to participate in the CLasP trial
Three patients (Mr Flynn, Mr Allgood and Mr
Frame) stated in the interview that they could not recall
the trial or being asked to participate. Two of these had
extremely low levels of recall of trial design issues (Mr
Flynn and Mr Allgood), but Mr Frame (an aeronautical
engineer) had very high levels of recall and indicated a
strong willingness to participate:
I don’t remember being asked at all [to take part in
the trial]. Now he may have said these things but I
certainly don’t remember. The reason I would have
responded in the way that I would have agreed for
trials was because all my life at British Aerospace I
was involved with engineering which involved a great
deal of testing and I know the benefits of going
through stringent testing and weighing this method
against that method, length of times, temperatures
and all sorts of things like that so had he asked me I
would have approved. [Mr Frame: non-participant
no reason given]
All three believed that they had been directed by the
clinician towards one treatment:
He said that I think it would be best if you didn’t go
in for it, so I left it like that. Now I’ve got to go again
in September. [Mr Flynn: non-participant treatment
preference]
So I said I’d like it done with the laser beam. So when
I went down again I seen Mr F and he said ‘you
wanted it done with the laser beam didn’t you’ and I
said yes. Well he said you can count that out. He said
if I do you with a laser beam he said it would damage
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your kidneys [y] so he said ‘what we’ve got to do is
we got to take the tissue out and that’s what they
done. [Mr Allgood: non-participant a dislike of
randomisation]
They seemed to say that your condition is not so
bad as to need surgery, therefore we recommend
you have tablets and that’s really how it was
presented to me. [y] and of course would be a
lot cheaper over the period of time, although it
would take longer to effect, I was quite happy
with that. [Mr Frame: non-participant no reason
given]
Discussion
This study shows that it is possible to engage trial
participants and non-participants in discussions about
their attitudes towards a trial, their allocated treatment,
and the method of allocation. Previous studies have
suggested that trial participants are confused about
randomisation and give distorted accounts (Snowdon
et al., 1997; Appelbaum et al., 1987). The men in this
study acknowledged that randomisation was confusing
and difficult, and many formed alternative accounts to
explain the treatment allocation. Superficially, these
accounts appeared contradictory and suggest confusion,
but seen in the context of the men’s experiences of some
of the trial procedures and their struggle to understand
the difficult concepts inherent in trial design, these
accounts were rational and reasonable.
There were a number of factors that contributed to
the men’s struggle to understand. It was clear that most
of these men were able to recall and understand aspects
of trial design, including randomisation. Such recall did
not, however, mean that such concepts made sense or
were believable. Allocation according to randomisation
appeared to some to be very haphazard (as is the lay
definition of the word (Feathersone & Donovan, 1998)).
It was difficult for these men to believe that such a
haphazard procedure was reasonable, particularly when
they had completed so many questionnaires about their
symptoms and undergone clinical tests, some of which
were very invasive. The men reasoned that the data from
the questionnaires and clinical tests must be useful, not
just for research purposes, but also for clinicians to
make individualised treatment decisionsFhence the
unacceptability of randomisation.
Participants adopted several approaches to making
sense of the trial. Some became distrustful because of
assumptions about the existence of rationing, others put
their trust in their clinician and their beliefs about fate
and destiny, while others just keep struggling with the
perceived inconsistencies. Thus, in attempting to make
sense of their participation, men produced narratives
which on one hand described their understanding of
elements of randomisation, but on the other hand
challenged aspects of trial design based on, for example,
their desire to trust clinicians to make treatment
allocations based on individual clinical characteristics,
or distrust relating to fears about rationing. Both the
participants and non-participants tried to make sense of
their experiences using similar rationalisations.
The evidence from this study suggests that non-
participation may be something of a lottery. While it
was reasonably clear that some of those labelled
‘refusers’ had expressed strong treatment preferences
and thus were rightly considered non-participants, there
were others who appeared to want to participate. There
were hints in some of their accounts that they had
expressed preferences, but some were surprised and
concerned that they had been labelled as non-partici-
pants. It would seem that the role of the clinician
recruiter was absolutely crucial in eliciting such prefer-
ences and deciding who should participate. Our focus
was on patient perceptions and so we did not have access
to what was actually said by recruiters, and this is an
area that urgently requires further research. It is
interesting that the non-participants were much more
aware and concerned than participants about the
‘experimental’ nature of the study and their perception
that they might be used as ‘guinea pigs’ might be an
important factor in refusing to participate.
Another interesting area for further research is in
patient preferences. While some work has been done in
this area (Silverman & Altman, 1996; McPherson, 1994)
this study suggests that patients may agree to randomi-
sation even when they have a preferred treatment. The
outcome of the randomisation may then have an impact
on their satisfaction with the study and, potentially,
their outcome. What we cannot tell in this study is
whether the treatment preferences expressed by these
men were held a priori, or whether they developed once
treatment had been assigned. Further work is required.
Much of the literature has concluded that providing
better or more information will resolve difficulties
inherent in the recruitment process. However, research
examining informed consent has found that even when
trials adhere to strict informed consent procedures and
ensure that ‘simple language’ is used, this does not
guarantee that subjects will fully understand the
implications of participation and that they may still
have unrealistic treatment expectations (Harth & Thong,
1995). It is true that clearer information in this trial
would have been beneficial, particularly about the use of
envelopes in the allocation procedure, but it is also clear
that this would not necessarily provide a solution. The
patient information in this study was well received and
largely accurately recalled, but patients still struggled
with the concepts underlying the design and developed
competing accounts to make sense of their experiences.
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It has been suggested that potential trial partici-
pants should be informed specifically about the compo-
nents of research that constitute a change from
the standard doctor–patient relationshipFrandomisa-
tion and blinding, plus any additional clinical examina-
tions and therapies (Editorial, BMJ, 1995). Edwards
et al. (1998) similarly conclude that abstract concepts
such as randomisation should receive particular
attention, ‘‘since it is the conceptual scientific basis of
trials rather than details of the treatments themselves
which patients find hard to grasp’’ (p. 53). It is also
important that participants understand clinical equi-
poise and thus have realistic expectations of the benefits
of trial participation. Clinicians are known to have
difficulty in expressing uncertainty, and perhaps it
should be some other member of the research team that
could be involved in explaining and discussing the
rationale for the trial. It is not clear who might be
suitable for this role (nurses? lay advocates?) and this
may also only provide a partial solution. Having the
chance to discuss these issues before making the decision
to participate may or may not help patients make sense
of the trial. It may also lead to lower rather than higher
levels of participation in trialsFthis remains to be
established.
There is some evidence from this study that the men’s
views may have had some impact on their outcome
following treatment. Some found the difficulty of
reconciling their views difficult and upsetting. In some
cases, patients became very cynical and some began to
doubt the veracity of the trial, considering it to be part
of some elaborate ‘con trick’ or resource-saving scheme.
These findings have implications for trial design and for
trialists as such beliefs may affect the internal and
external validity of a trial.
It is important to consider the potential limitations to
this study. It has included only men, and only relatively
small numbers involved in this trial. Also, interviews
were conducted after these men had been asked to
participate, and so we do not know how their views
changed during the recruitment process or how their
preferences for particular treatments might have chan-
ged. There are, however, a number of themes from this
study that find echoes in previous research, particularly
conducted by Snowdon et al. (1997) and Appelbaum
et al. (1987) about the difficulties participants have in
understanding randomisation. This study extends this
work by showing that participants engage in an ongoing
struggle to understand the methods of the trial and the
process by which they are allocated treatment. It will be
important for further research to investigate whether
this struggle is found more widely in other trials and
other patient groups. Another very useful avenue for
further research would be to examine the struggle in the
context of participants’ beliefs before their involvement
in the trial.
This study used qualitative research methods to
explore the experience of participation in a trial. If a
structured questionnaire had been used to assess recall
and understanding, it is likely that the majority of these
participants would have been shown to be aware that
they were taking part in a trial and to have understood
some or most of the basic aspects of the design. There
was some evidence of confusion about key concepts, as
has been found in previous studies, but we have shown
that these men tried to make sense of their involvement
in the trial rationally and sensibly in relation to their
own beliefs, their recall of the study information, and
their actual experiences. As they engaged in the struggle,
some found peace of mind in their trust of the clinicians,
others became very cynical about the study, and the
remainder continued to struggle. One conclusion might
be that more information should be provided for
potential participantsFsuch as clearer written informa-
tion or time to discuss the issues with particular
individuals. Such interventions require further research,
but the findings from this study suggest that most
participants (and non-participants), whatever their level
of knowledge, will struggle to make sense of the need for
randomised trials. Perhaps the greatest need is for more
open debate about trials amongst trialists, recruiting
clinicians and the public.
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